Corbus Pharmaceuticals Holdings Inc. Common Stock (CRBP)
Stock · NASDAQ · Health Care
$4.51as of 10/16/2026
Price chart
Active signals
CRBP Signal Track Record
How signals performed across all stocks →What CRBP's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 37 | -6.6% | 43% | September 1, 2026 |
| Bollinger Band Breakdown | 23 | -3.3% | 39% | September 9, 2026 |
| Bollinger Band Breakout | 23 | +2.6% | 57% | August 25, 2026 |
| 200-Day Moving Average TouchActive now | 8 | +5.8% | 50% | August 6, 2026 |
| Any 20-session window (baseline) | -1.1% | 48% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CRBP
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 36
- Website
- www.corbuspharma.com/
Fundamentals
- 1-day range
- $4.23$4.62
- Market cap
- $180.46M
- P/E (trailing)
- —
- P/E (forward)
- -0.80
- EPS (trailing)
- $-6.17
- Dividend yield
- —
- Beta
- 2.74
- Avg. volume
- 798.4K
How Corbus Pharmaceuticals Holdings Inc. Common Stock Makes Money
Where the revenue actually goes — FY2021 annual results
Source: 10-K filed Mar 8, 2022 · via SEC EDGAR / Finnhub
Forecasts
10 analyst ratings
Corbus Pharmaceuticals Holdings Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CRBPCorbus Pharmaceuticals Holdings Inc. Common Stock$4.52▲ 4.39%Market cap $180.46MP/E —$4.37$20.56
- DERMJourney Medical Corporation Common Stock$4.97▼ 3.12%Market cap $179.80MP/E —$4.31$9.56
- LFCRLifecore Biomedical Inc. Common Stock$6.38▼ 0.93%Market cap $181.55MP/E —$3.63$8.98
- ORMPOramed Pharmaceuticals Inc. Common Stock$4.07▼ 2.63%Market cap $178.87MP/E 0.98$2.09$5.47
- TNXPTonix Pharmaceuticals Holding Corp. Common Stock$6.04▼ 5.92%Market cap $185.71MP/E —$6.01$20.69
- KRROKorro Bio Inc. Common Stock$8.49▼ 8.81%Market cap $174.80MP/E —$5.2$55.89
- ARCTArcturus Therapeutics Holdings Inc. Common Stock$10.34▼ 8.25%Market cap $172.81MP/E —$5.5$24.17
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CRBP Corbus Pharmaceuticals Holdings Inc. Common Stock | $180.46M | — | $4.52 | ▲ 4.39% | $4.37$20.56 |
| DERM Journey Medical Corporation Common Stock | $179.80M | — | $4.97 | ▼ 3.12% | $4.31$9.56 |
| LFCR Lifecore Biomedical Inc. Common Stock | $181.55M | — | $6.38 | ▼ 0.93% | $3.63$8.98 |
| ORMP Oramed Pharmaceuticals Inc. Common Stock | $178.87M | 0.98 | $4.07 | ▼ 2.63% | $2.09$5.47 |
| TNXP Tonix Pharmaceuticals Holding Corp. Common Stock | $185.71M | — | $6.04 | ▼ 5.92% | $6.01$20.69 |
| KRRO Korro Bio Inc. Common Stock | $174.80M | — | $8.49 | ▼ 8.81% | $5.2$55.89 |
| ARCT Arcturus Therapeutics Holdings Inc. Common Stock | $172.81M | — | $10.34 | ▼ 8.25% | $5.5$24.17 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal CancerYahoo · 9/29/2026
- Corbus Pharmaceuticals Holdings, Inc. (CRBP) Phase 1b Topline Results for CRB-913 in Obesity and Potential as Weight Loss Therapy - SlideshowSeekingAlpha · 9/17/2026
- Is CRBP a Good Cannabis Investment After Positive Obesity Study Data?Yahoo · 9/17/2026
- Corbus CRB-913 Delivers 5% Weight Loss in Phase 1b Obesity StudyYahoo · 9/15/2026
- Corbus Pharmaceuticals Shares Rise 12% After CANYON-1 Obesity Trial DataYahoo · 9/14/2026
- Corbus Pharmaceuticals Holdings, Inc. (CRBP) Phase 1b Topline Results for CRB-913 in Obesity and Potential as Weight Loss Therapy TranscriptSeekingAlpha · 9/14/2026
- HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $35 Price TargetBenzinga · 9/14/2026
- Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of ObesityYahoo · 9/14/2026
Insider Activity
Insider Actions →- Yong Ben · September 14, 2026 · Sale2.0K @ $7.84
- Leonardo Viana Nicacio · August 16, 2026 · Grant191.7K
- Leonardo Viana Nicacio · August 16, 2026 · Grant58.3K
- Nishant C. Saxena · August 11, 2026 · Buy2.6K @ $9.63
- Yuval Cohen · August 7, 2026 · Sale17.0K @ $10.08
- Sean F. Moran · August 7, 2026 · Sale12.0K @ $10.08
- Winston Kung · June 10, 2026 · Sale2.0K @ $7.91
- John Kenneth Jenkins · June 10, 2026 · Sale4.8K @ $7.91
- Anne Altmeyer · June 10, 2026 · Sale2.4K @ $7.91
- Nishant C. Saxena · June 3, 2026 · Buy9.0K @ $7.58
- Nishant C. Saxena · June 2, 2026 · Buy4.5K @ $7.33
- Nishant C. Saxena · May 21, 2026 · Grant192.3K
- Nishant C. Saxena · May 21, 2026 · Grant58.3K
- Rachelle Suzanne Jacques · May 19, 2026 · Grant3.8K
- Winston Kung · May 19, 2026 · Grant12.3K
Institutional Ownership
March 31, 2026
- Total shares held
- 13.05M
- Total value held
- $121.27M
- Institutional holders
- 102
- Unknown2.34M
- Unknown1.74M
- Unknown1.32M
- Unknown806.6K
- Unknown734.1K
- Unknown697.1K
- Unknown555.3K
- Unknown418.3K
- Unknown383.5K
- Unknown366.8K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Corbus Doses First Patient in CRB-701 TEMPO-1 Study
Corbus Pharmaceuticals announced that the first patient has been dosed in the TEMPO-1 registrational study for CRB-701. This clinical trial focuses on patients with second-line or later oropharyngeal cancer. The update marks a significant step in the development timeline for the company's lead asset.
Corbus Doses First Patient in CRB-701 TEMPO-1 Study. Corbus Pharmaceuticals announced that the first patient has been dosed in the TEMPO-1 registrational study for CRB-701. This clinical trial focuses on patients with second-line or later oropharyngeal cancer. The update marks a significant step in the development timeline for the company's lead asset.